{"prompt": "['23', 'operative pain not only reduced pain levels and opioid consumption relative to sham-treated', 'patients, but was also associated with lower IL-1B levels in post-operative wound exudates.24', 'Together, these findings suggest that PEMF therapy reduces pain both by modulating inflammation', 'and by activating peripheral endogenous opioids.', 'In vitro studies have provided evidence that PEMF therapy improves nerve growth and may', 'improve nerve function through up-regulation of genes involved in neurogenesis (data on file). In', 'addition, genes related to angiogenesis have also been shown to be up-regulated.', 'An exploratory prospective randomized, sham-controlled study was recently conducted at two sites', 'using the Provant Therapy System to (a) evaluate small fiber nerve growth and function in subjects', 'with painful peripheral diabetic neuropathy and to (b) determine the safety and feasibility of Provant', 'in such subjects. Twenty-three subjects with painful peripheral diabetic neuropathy were treated for', '60 days with twice-daily PEMF therapy. Subjects were eligible for enrollment if they had type 2', 'diabetes with persistent numbness, tingling, or burning in at least one foot despite standard of care', 'treatment.', 'Nineteen subjects in this study were evaluated for the effectiveness of the Provant Therapy System', 'in enhancing small fiber nerve growth and function. PEMF treatment twice daily for 60 days was', 'associated with improved skin perfusion pressure, and improved nerve conduction velocity,', 'although no consistent changes were observed in self-reported pain scores based on paper diaries.', 'The twice daily application of PEMF was determined to be feasible and safe in subjects with DSPN.', 'The purpose of the current study is to evaluate the efficacy and safety of PEMF treatment with the', 'Provant\u00b0 R Therapy System. The current study focuses on pain relief and self-reported functional', 'improvement as well as objective measures that may further elucidate the basic mechanisms of the', 'intervention. The current study will use electronic diaries rather than paper diaries and include', 'a', 'larger sample size to improve the reliability and precision of the result.', '710-7105-01 C', 'RBI.2017.002 Version C', 'CONFIDENTIAL']['24', '2.', 'STUDY OBJECTIVES', 'This study is designed to evaluate the efficacy of dual field PEMF Therapy [Provant', 'Therapy System] compared to sham treatment in patients with painful diabetic distal', 'symmetric peripheral neuropathy (DSPN) when treatment is administered, 30 minutes twice', 'daily through a 120-day period (4 months).', '710-7105-01 C', 'RBI.2017.002 Version C', 'CONFIDENTIAL']['25', '3.', 'STUDY DESIGN', '3.1', 'Study Design', 'Part A of the study is a double-blind, sham-controlled, randomized trial of the safety and', 'efficacy of dual field PEMF therapy in subjects with bilateral symmetrical painful diabetic', 'distal symmetric peripheral neuropathy (DSPN). A graphic presentation of the study design', 'for Part A is shown in Figure 1. Part B of the study is an 8-month open-label active treatment', 'extension period. A graphic presentation of the study design is shown in Figure 2.', 'Figure 1. Part A Study Flow Schematic', 'Screening Visit (Day -15)', 'Assess eligibility and enter subject in 14-day run-in period', 'Enrollment Visit (Day 0)', 'Review eligibility from ePRO, Work Productivity and Activity Impairment Questionnaire,', 'NeuroQoL, patient global impression, DSPN assessments, adverse events, and randomization', '7-Day Follow-Up Phone Call', 'Assess subject adherence, adverse events, and concomitant medications', '1 Month Interim Visit (Day 30)', 'Assess subject adherence, adverse events, patient global impression, and concomitant', 'medications', '2 Month Interim Visit (Day 60)', 'Assess subject adherence, adverse events, patient global impression, and concomitant', 'medications', '3 Month Interim Visit (Day 90)', 'Assess subject adherence, adverse events, patient global impression, and concomitant', 'medications', '4 Month End of Part A Study Visit (Day 121), Start of Part B', 'Assess subject adherence, adverse events, WPAIQ, NeuroQoL, patient global impression,', 'DSPN assessments, concomitant medications, and device return. Part B Enrollment and', 'dispensing of Active device', '710-7105-01 C', 'RBI.2017.002 Version C', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}